- Význam blokády CTLA-4 v léčbě onkologických onemocnění: ipilimumab, monoklonální protilátka tlumící imunosupresivní signální aktivitu CTLA-42021 | First Faculty of Medicine
- Therapeutic options for CTLA-4 Insufficiency2022 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Immunotherapy for metastatic melanoma2015 | Publication without faculty affiliation
- Advances in immunotherapy of melanoma2016 | Publication without faculty affiliation
- New trends in immunotherapy of melanoma2020 | First Faculty of Medicine
- CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade2021 | Faculty of Science
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- IIpilimumab in the treatment of melanoma2014 | Third Faculty of Medicine
- Possible Pitfalls of Ipilimumab Therapy in Malignant Melanoma - a Case Report2015 | Faculty of Medicine in Hradec Králové
- Immune-related adverse events2017 | Faculty of Medicine in Hradec Králové
- IL-7/αIL-7 mAb M25 immunocomplexes expand CD8+ T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage2020 | Second Faculty of Medicine
- Immunoterapy related toxicities2017 | Faculty of Medicine in Hradec Králové
- Nežádoucí účinky imunoterapie monoklonálními protilátkami proti CTLA-4 a PD-12016 | Publication without faculty affiliation
- Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer2020 | Faculty of Medicine in Hradec Králové
- Melanom - současné a budoucí trendy léčby2017 | Publication without faculty affiliation
- Immuno-oncological treatment of melanoma2014 | Publication without faculty affiliation
- Advances in the treatment of metastatic melanoma2013 | Publication without faculty affiliation
- Immunotherapy of malignant melanoma2015 | Publication without faculty affiliation
- Možnosti léčby metastazujícího melanomu v kazuistikách2017 | Publication without faculty affiliation
- Imunoterapie a molekulárně cílená léčba u maligního melanomu2022 | First Faculty of Medicine
- Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis2000 | Faculty of Medicine in Hradec Králové
- Activated Phosphoinositide 3-Kinase δ Syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity2023 | Second Faculty of Medicine
- Comments on the Clinical Development of Ipilimumab2013 | Publication without faculty affiliation
- Pembrolizumab v terapii slizničního melanomu2016 | First Faculty of Medicine
- News in immunotherapy of dMMR/MSI-H CRC2022 | Third Faculty of Medicine
- The Abscopal Effect in the Era of Checkpoint Inhibitors2021 | First Faculty of Medicine
- Distinct characteristics of Tregs of newborns of healthy and allergic mothers2018 | First Faculty of Medicine
- Adverse Effects of Modern Treatment of Malignant Melanoma and their Treatment/Management2014 | Faculty of Medicine in Hradec Králové
- Biologická léčba melanomu2016 | Publication without faculty affiliation
- Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport